Aldosterone blockade in post‐acute myocardial infarction heart failure by Pitt, Bertram et al.
Aldosterone Blockade in Post-Acute Myocardial Infarction Heart Failure
BERTRAM PITT, M.D., ROBERTO FERRARI, M.D.,*   MIHAI GHEORGHIADE, M.D.,†   DIRK J. VAN VELDHUISEN, M.D., PH.D.,‡   
HENRY KRUM, M.D., PH.D.,§   JOHN MCMURRAY, M.D.,||   JOSE LOPEZ-SENDON, M.D.#
University of Michigan Medical Center, William Beaumont Hospital, Ann Arbor, Michigan, USA;  *University Hospital of Ferrara,
Ferrara, Italy; †Northwestern University, Chicago, Illinois, USA;  ‡University Hospital Groningen, Groningen, The Netherlands;
§Monash University, Melbourne, Australia;  ||University of Glasgow, Glasgow, Scotland;  #La Paz University Hospital, Madrid, Spain
Summary: Development of heart failure (HF) or left ventric-
ular systolic dysfunction (LVSD) significantly increases mor-
tality post acute myocardial infarction (AMI). Aldosterone
contributes to the development and progression of HF post
AMI, and major guidelines now recommend aldosterone
blockade in this setting. However, lack of practical experience
with aldosterone blockade may make clinicians hesitant to
use these therapies. This review is based on a consensus car-
diology conference that occurred in May 2005 (New York
City) concerning these topics. Potential barriers to the use of
aldosterone blockade are discussed and an algorithm for ap-
propriate in-hospital pharmacologic management of AMI
with LVSD and/or HF is presented.
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Introduction
Aldosterone has emerged as an important risk factor in 
patients with heart failure (HF). This is underscored by two
large-scale clinical trials, the Randomized Aldactone Evalu-
ation Study (RALES)1 and the Eplerenone Post-Acute Myo-
cardial Infarction (AMI) Heart Failure Efficacy and Survival
Study (EPHESUS).2 These trials demonstrated significant im-
provements in mortality and morbidity with aldosterone
blockers added to standard therapy in patients with chronic, se-
vere systolic HF and in patients with left ventricular systolic
dysfunction (LVSD; left ventricular ejection fraction [LVEF]
≤40%) and HF following an AMI, respectively.
This review focuses on aldosterone blockade specifically in
patients with post-AMI HF and LVSD and proposes a practi-
cal treatment algorithm to assist clinicians in providing opti-
mal care to these patients.
The Burden of Post-Acute Myocardial Infarction
Heart Failure and the Role of Aldosterone
The development of HF and/or LVSD significantly increas-
es morbidity and mortality post AMI.3–7 It is estimated that 20
to 40% of patients with AMI will develop HF.3, 4, 7 Patients
post AMI with HF and/or LVSD have a 3- to 4-fold increased
risk of in-hospital death, as well as significant increases in 30-
day mortality, long-term mortality, and rehospitalization rates
compared with patients with AMI and without HF.3–6 Re-
cently, it has been shown that the first 30 days post infarction is
the period of highest risk in patients with LVSD, especially for
sudden cardiac death (Fig. 1).8 This occurs despite routine
treatment with angiotensin-converting enzyme (ACE) inhibi-
tors/angiotensin receptor blockers (ARBs) and beta blockers.8
Some of the cardiovascular effects of aldosterone that may
contribute to the development and progression of post-AMI
HF include myocardial and vascular fibrosis, catecholamine
potentiation, potassium and magnesium loss, ventricular ar-
rhythmias, cardiomyocyte apoptosis, sodium retention, ische-
mic injury, and endothelial dysfunction.9–12 Animal and hu-
man models have demonstrated reversal of these harmful patho-
physiologic effects with aldosterone blockade post AMI.12–15
Based on the above, EPHESUS was designed to explore the
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impact of the selective aldosterone blocker eplerenone on mor-
tality and morbidity in patients with AMI complicated by
LVSD and HF.2
Eplerenone Post-Acute Myocardial Infarction Heart
Failure Efficacy and Survival Study (EPHESUS)
Clinically stable patients with LVEF ≤ 40% and HF or dia-
betes were randomized 3 to 14 days after AMI to receive
eplerenone (25 mg/day increased to 50 mg/day after 4 weeks)
or placebo.2 After a mean follow-up of 16 months, eplere-
none significantly reduced the risk of all-cause mortality by
15% (p = 0.008), cardiovascular mortality/cardiovascular
hospitalization by 13% (p = 0.002), cardiovascular mortality
by 17% (p = 0.005), and sudden cardiac death by 21% (p =
0.03) in patients already receiving standard therapy, including
ACE inhibitors (87% of patients) and beta blockers (75% 
of patients).
The significant beneficial effects of eplerenone were seen as
early as 30 days post randomization, although patients were
not titrated to the target dose (50 mg) until Month 1.16 The risk
of all-cause mortality was reduced by 31% (p = 0.004) and the
risk of sudden cardiac death was reduced by 37% (p = 0.051)
during this early period. This is particularly noteworthy given
that the risk for sudden death in this population is highest dur-
ing this time period (Fig. 1)8 and also considering that other
therapies, including implantable cardioverter defibrillators,17
have failed to demonstrate incremental benefit when used with
standard treatment during this high-risk period. This under-
scores the importance of early initiation of aldosterone block-
ade in patients with post-AMI LVSD and HF. Figure 2 shows
early and long-term mortality benefits in EPHESUS.2, 16
Barriers to Implementation of Aldosterone Blockade
in Post-Acute Myocardial Infarction Heart Failure
Major therapeutic guidelines for AMI and HF now include
specific recommendations for the use of aldosterone blockade
in addition to other well-accepted life-saving therapies (Table
I).18–20 However, the lack of practical experience with aldos-
terone blockers in patients post AMI with LVSD and HF pos-
es barriers to implementation.
How to Manage Patients Who Cannot Be Titrated to the
Target Dose
A recent subanalysis of EPHESUS demonstrated that pa-
tients unable to achieve the target dose of 50 mg experienced
significant reductions in endpoints with a dose of 25 mg/day,
or even 25 mg every other day.21 Significant reductions in all-
cause mortality (by 34%, p < 0.001), cardiovascular mortali-
ty/cardiovascular hospitalization (by 22%, p = 0.009), cardio-
vascular mortality (by 36%, p < 0.001), and sudden cardiac
death (by 35%, p = 0.03) were achieved. 
Risk of Hyperkalemia Secondary to Aldosterone Blockade 
In EPHESUS, the incidence of hyperkalemia (serum potas-
sium > 6.0 mmol/l) was greater with eplerenone than with
placebo (5.5 vs. 3.9%), but discontinuation due to hyperkale-
mia was <1% in both treatment groups, and no deaths in epler-
enone-treated patients were attributable to hyperkalemia.2
Reports of excess hyperkalemia secondary to spironolac-
tone use appeared after publication of RALES.22 However, 
patients in these reports were much older, had higher pretreat-
ment creatinine values, were exposed to higher doses of spir-
onolactone than in RALES, and may not have had serial potas-
sium monitoring with dose adjustment for serum potassium
> 5.5 mmol/l or discontinuation for serum potassium > 6.0
mmol/l.23, 24 As demonstrated in EPHESUS, proper patient se-
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FIG. 1 The rate of sudden death or cardiac arrest with resuscitation
by category of left ventricular ejection fraction (LVEF) in the
VALIANT trial.8 The rate of events was highest in all patients during
the first 30 days post infarction and in those with the most compro-
mised LVEF. Adapted from Ref. No. 8 with permission.
FIG. 2 The reduction in early (30 days post randomization) and
long-term (mean 16-month follow-up) mortality with eplerenone
used in addition to standard therapy in EPHESUS.2, 16 
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lection, monitoring, and dose adjustments can minimize the
risk of hyperkalemia associated with aldosterone blockade
(Table II).24
Fear that Adding Eplerenone to Standard Therapy Post
Acute Myocardial Infarction May Result in Hypotension 
Retrospective analysis of EPHESUS data has revealed that
adding eplerenone to ACE inhibitors/ARBs and beta blockers
did not result in hypotension compared with placebo either
early (1-week) or late (mean 16-month follow-up) post AMI
(data on file). Patients in the lowest baseline systolic blood
pressure (SBP) quartile showed no mean decrease in SBP,
whereas patients in the highest quartile had a mean SBP de-
crease into the normal range.
Uncertainty of Benefit in Patients Who Are Reperfused and
thus May Have Only Transient Heart Failure or 
Left Ventricular Systolic Dysfunction
In EPHESUS, the evidence of LVSD and/or HF could
have been transient, occurring any time from onset of the in-
TABLE I Major therapeutic guidelines including a recommendation for aldosterone blockade in patients with post-AMI LVSD and HF
Class of recommendation/ 
Guideline level of evidence a Comments
American College of Cardiology (ACC)/ Class I/Level A Aldosterone blockade should be used in patients post 
American Heart Association (AHA) STEMI  without significant renal dysfunction or 
guidelines for treatment of patients hyperkalemia who are already receiving an ACE 
with ST-segment elevation myocardial inhibitor, have LVEF  ≤40%, and have either 
infarction (STEMI)18 symptomatic HF or diabetes
ACC/AHA guidelines for management Class I/Level B Aldosterone blockade should be used in patients with 
of chronic HF19 moderate to severe HF and reduced LVEF who can be
monitored for preserved renal function and normal
potassium concentration
European Society of Cardiology Class I/Level B Aldosterone blockade should be used in addition to 
guidelines for management of ACE inhibitors and beta blockers in patients post 
chronic HF20 AMI with LVSD and signs of HF or diabetes
a Class I: Conclusive evidence and/or general agreement that a given treatment is useful, beneficial, and effective. Level of evidence A: Data are
derived from multiple randomized clinical trials or meta-analyses; level of evidence B: Data are derived from a single randomized trial, or non-
randomized studies.
Abbreviations: ACE = angiotensin-converting enzyme, AMI = acute myocardial infarction, HF = heart failure, LVEF = left ventricular ejection
fraction, LVSD = left ventricular systolic dysfunction.
TABLE II Administration and dosing considerations for aldosterone blockers19, 20
1. Serum potassium should be <5.0 mmol/l and serum creatinine should be <2.5 mg/dl prior to initiation
2. Impaired renal function is a risk factor for hyperkalemia; the risk of hyperkalemia increases when serum creatinine > 1.6 mg/dl. In elderly 
patients or others with low muscle mass in whom serum creatinine does not accurately reflect glomerular filtration rate (GFR), determination
that GFR or creatinine clearance >30 ml/min is recommended
3. Potassium supplements should be discontinued or reduced
4. An initial dose of eplerenone 25 mg/day or spironolactone 12.5–25 mg/day is recommended
5. Close monitoring of serum potassium is required; potassium levels and renal function should be checked in 3 days and 1 week after initiation
of therapy and dosage changes, and at least monthly for the first 3 months
6. If at any time serum potassium ≥5.5 mmol/l, reduce dose by 50% (or dose on alternate days if patient is already on lowest dose). Withhold
dose if serum potassium ≥6.0 mmol/l and restart once potassium <6.0 mmol/l
7. If normokalemia exists after 1 month, increase dosage to 50 mg/day
8. Nonsteroidal anti-inflammatory drugs and cyclo-oxygenase-2 inhibitors should be avoided. If initiated, potassium and renal function should
be checked within 1 week
9. If diarrhea or vomiting occurs, the aldosterone blocker should be stopped until resolution. Caution is also necessary when there are other po-
tential causes of dehydration, including increase in diuretic dose
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dex AMI, and did not need to be present at randomization.2
It is possible that LVEF had improved by randomization due
to recovery from myocardial stunning, hibernation, improved
myocardial compliance, reperfusion, and pharmacologic
treatment with ACE inhibitors, nitrates, beta blockers, and
diuretics. Thus, while physicians should require evidence of
LVSD and HF on admission post AMI, neither LVSD nor HF
needs to persist to initiate eplerenone.
The Cost of Eplerenone
Cost can be an important barrier to the use of evidence-
based therapies in the clinical setting. A recent analysis deter-
mined that eplerenone, compared with placebo in the treat-
ment of LVSD and HF post AMI, is cost effective in increasing
years of life, with an overall incremental cost of approximate-
ly $13,700 per quality-adjusted life-year gained25; this is be-
low the $50,000 threshold commonly used to determine whe-
ther a medication is a good value and is comparable with that
of many other well-accepted cardiovascular medications, in-
cluding ACE inhibitors and beta blockers. 
While spironolactone offers a less expensive alternative to
eplerenone for aldosterone blockade, caution should be ex-
ercised in applying the dosing strategy of spironolactone
used in RALES to patients with post-AMI LVSD and HF, as
long-term outcomes have not been evaluated in this setting.
Because spironolactone is a more potent, although less spe-
cific, inhibitor of the mineralocorticoid receptor than epler-
enone, it is possible that use of spironolactone beginning
with 25 mg/day could result in hypotension or excess hyper-
kalemia in these patients.
Recommendations for the appropriate use of aldosterone
blockade, adapted from the American College of Cardiology/
American Heart Association (ACC/AHA)19 and European
Society of Cardiology (ESC)20 guidelines for chronic HF, are
given in Table II. 
A Treatment Algorithm to Improve Outcomes in 
Post-Acute Myocardial Infarction Heart Failure
The algorithm in Figure 3 outlines appropriate in-hospital
pharmacologic management of AMI with LVSD and/or HF
based on current clinical evidence and available guidelines.
This includes the addition of aldosterone blockade as essential
adjunctive treatment for eligible patients in this setting.
Despite serious risks of mortality and hospitalizations asso-
ciated with development of HF and/or LVSD in patients with
AMI,3–6 these patients are less likely to be treated with life-
saving, guideline-recommended therapies than those with
AMI and without HF.3, 4 Wu et al.4 demonstrated that 75% of
patients with AMI and HF were not treated with ACE in-
hibitors or beta blockers, and 25% did not receive aspirin, al-
though these treatments provided the strongest protection
against in-hospital death in patients with HF (odds ratio 0.51,
0.42, and 0.42 for ACE inhibitor, beta blocker, and aspirin, re-
spectively). Treatment rates for patients with AMI without HF
were significantly better (p<0.001) (Fig. 4).
New approaches to increasing early initiation and consis-
tent use of guideline-recommended, life-prolonging therapies
in eligible patients (Fig. 3) are fundamental to reducing ex-
cessive mortality and morbidity in this high-risk population.
These new approaches include HF disease management pro-
grams and clinical pathways, which have been shown to im-
prove the routine in-hospital initiation of treatments, long-
term compliance, and patient outcomes.26
Conclusion
Aldosterone blockade offers significant incremental benefit
for reducing mortality and morbidity above and beyond other
Acute myocardial infarction
Estimation of LV function
LVSD (LVEF  ≤ 40%)
Recommended secondary preventive therapies
• ACE inhibitor (or an ARB, if intolerant of ACE inhibitors)
• Oral beta blocker
• Aldosterone blocker
• Antiplatelet agents (ASA/clopidogrel)
• Statin
• Antithrombotic agents
➪
➪
➪
FIG. 3 Pharmacologic treatment algorithm for patients post myocar-
dial infarction with left ventricular systolic dysfunction (LVSD).
LVEF = left ventricular ejection fraction, ACE = angiotensin-con-
verting enzyme, ARB = angiotensin receptor blocker, ASA = aspirin.
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FIG. 4 Utilization of evidence-based therapies in patients with acute
myocardial infarction with/without heart failure (HF), on hospital ad-
mission.4 ACE = angiotensin-converting enzyme, IV = intravenous.
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proven therapies for post-AMI HF and should be prescribed
for all eligible patients. In view of the high early mortality in
this population, it is important to start an aldosterone blocker in
these patients as soon as they are hemodynamically stable.
The widespread use of an aldosterone blocker in eligible pa-
tients with HF post AMI will have important implications for
improved mortality and morbidity as well as important reduc-
tions in health care costs.
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